Company profile
GENMAB A/S
NASDAQ:GMABBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EPKINLY | approved | — | 0 | — |
| GOLCADOMIDE | phase3 | — | 11 | active |
| TIXESTOBART | phase1_2 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (67)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06771921 | phase1_2 | terminated | 2025-01-29 | 2025-06-11 | Genmab | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors |
| NCT06018129 | phase1_2 | terminated | 2023-09-21 | 2025-02-05 | Genmab | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
| NCT07695831 | phase1 | recruiting | 2026-08-13 | 2029-06-01 | Genmab | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors |
| NCT06685068 | phase1_2 | terminated | 2024-11-13 | 2026-03-30 | Genmab | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors |
| NCT04628494 | phase3 | active_not_recruiting | 2021-01-13 | 2025-10-13 | Genmab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761324 | 2023-05-19 | BLA | GENMAB US, INC. | |||||
Loading… | ||||||||